

Global Oncology Biosimilars Market

<https://marketpublishers.com/r/G9EFA4B13E29EN.html>

Date: December 2025

Pages: 173

Price: US\$ 4,650.00 (Single User License)

ID: G9EFA4B13E29EN

Abstracts

Summary:

The global market for oncology biosimilars is estimated to grow from \$9.6 billion in 2025 and projected to reach \$17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.

Oncology biosimilars leverage advanced algorithms and machine learning to optimize the entire clinical R&D process. These technologies streamline trial design, patient recruitment, monitoring and data analysis, enabling faster and more accurate decision-making. By reducing operational inefficiencies and timelines, oncology biosimilars development benefits from real-time, data-driven insights that support precision medicine approaches. Integrating tools such as predictive analytics, natural language processing and adaptive monitoring ensures that oncology biosimilar trials are not only more efficient but also better aligned with the complexities of cancer care, ultimately accelerating the availability of cost-effective biologic alternatives. The global oncology biosimilars market was valued at \$REDACTED in 2024 and is expected to reach \$REDACTED by the end of 2030. The market is expected to grow at a CAGR of REDACTED% during the forecast period.

Report Scope

The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by

distribution channel.

Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.

It includes global revenue (\$ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.

Report Includes

140 data tables and 40 additional tables

In-depth analysis of the global market for oncology biosimilar drugs

Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030

Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region

Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables

Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care

Insights derived from Porter's Five Forces model, as well as global supply chain analyses

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

A relevant patent analysis, featuring key granted and published patents

Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook

Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

CHAPTER 2 MARKET OVERVIEW

Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Economic Growth and Development
Demographic Shifts
Healthcare Expenditure Trends
Inflation and Currency Fluctuations
Porter's Five Forces Analysis

CHAPTER 3 MARKET DYNAMICS

Overview
Market Drivers
Surge in Global Cancer Incidence
Expiration of Blockbuster Biologic Patents
Need for Cost-Effective Cancer Therapies
Demand for Targeted and Supportive Oncology Treatments
Market Restraints
Regulatory Complexity and Approval Hurdles
Patent Challenges and Legal Barriers
Pharmacy Benefit Manager Practices
Market Opportunities

Expansion into Emerging Markets

Development of Novel Biosimilar Combinations and Specialty Formulations

CHAPTER 4 REGULATORY LANDSCAPE

Regulatory Framework

U.S.

Europe

India

Australia

Japan

CHAPTER 5 EMERGING TECHNOLOGIES AND NEW DEVELOPMENTS

Overview

Emerging Technologies

Advanced Cell Line Engineering

Artificial Intelligence and Machine Learning in Biosimilar Development

Gene Editing and Synthetic Biology Approaches

Modular and Single-Use Bioreactors

Patent Analysis

Key Takeaways

Patents, by Year

Patents, by Leading Jurisdiction

Patents, by Leading Inventor

CHAPTER 6 MARKET SEGMENTATION ANALYSIS

Segmentation Breakdown

Global Oncology Biosimilars Market, by Indication

Key Takeaways

Breast Cancer

Lung Cancer

Blood Cancer

Others

Global Oncology Biosimilars Market, by Drug Class

Key Takeaways

Granulocyte Colony-Stimulating Factor

Monoclonal Antibodies

Hematopoietic Agents

Others

Global Oncology Biosimilars Market, by Route of Administration

Key Takeaways

Intravenous

Subcutaneous

Others RoA

Global Oncology Biosimilars Market, by Distribution Channel

Key Takeaways

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Geographic Breakdown

Global Oncology Biosimilars Market, by Region

Key Takeaways

North America

Europe

Asia-Pacific

Middle East and Africa

South America

CHAPTER 7 COMPETITIVE INTELLIGENCE

Industry Structure

Company Share Analysis for Oncology Biosimilars Market

Strategic Analysis

CHAPTER 8 SUSTAINABILITY IN THE ONCOLOGY BIOSIMILARS MARKET: ESG PERSPECTIVE

Introduction to ESG

Sustainability Trends and Initiatives of the Oncology Biosimilars Industry

Concluding Remarks

CHAPTER 9 APPENDIX

Methodology

Abbreviations

Company Profiles

ACCORD HEALTHCARE

ALVOTECH

AMGEN INC.

AMNEAL PHARMACEUTICALS LLC.

APOTEX INC.

BIOCAD

BIOCON BIOLOGICS LTD.

CELLTRION INC.

FRESENIUS KABI AG

PFIZER INC.

SAMSUNG BIOEPIS

SANDOZ GROUP AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

VIATRIS INC.

Emerging Start-ups/Market Disruptors

List Of Tables

LIST OF TABLES

Summary Table : Global Market for Oncology Biosimilars, by Region, Through 2030

Table 1 : Real GDP Growth, by Country, 2022–2025

Table 2 : Pricing Analysis for Oncology WAC and ASP, 2024

Table 3 : Patents Granted for Oncology Biosimilars, by Year, 2022–2025

Table 4 : Patents Granted for Oncology Biosimilars, by Top Jurisdiction, 2022–2025

Table 5 : Patents Granted for Oncology Biosimilars, by Top Inventor, 2022–2025

Table 6 : Global Market for Oncology Biosimilars, by Indication, Through 2030

Table 7 : Global Market for Breast Cancer, by Region, Through 2030

Table 8 : Global Market for Lung Cancer, by Region, Through 2030

Table 9 : Global Market for Blood Cancer, by Region, Through 2030

Table 10 : Global Market for Other Types of Cancer, by Region, Through 2030

Table 11 : Global Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 12 : Global Market for Granulocyte Colony-Stimulating Factor, by Region, Through 2030

Table 13 : Global Market for Monoclonal Antibodies, by Region, Through 2030

Table 14 : Global Market for Hematopoietic Agents, by Region, Through 2030

Table 15 : Global Market for Other Drug Classes, by Region, Through 2030

Table 16 : Global Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 17 : Global Market for Intravenous Route of Administration, by Region, Through 2030

Table 18 : Global Market for Subcutaneous Route of Administration, by Region, Through 2030

Table 19 : Global Market for Other Routes of Administration, by Region, Through 2030

Table 20 : Global Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 21 : Global Market for Hospital Pharmacies for Oncology Biosimilars, by Region, Through 2030

Table 22 : Global Market for Retail Pharmacies for Oncology Biosimilars, by Region, Through 2030

Table 23 : Global Market for Online Pharmacies for Oncology Biosimilars, by Region, Through 2030

Table 24 : Global Market for Other Distribution Channels for Oncology Biosimilars, by Region, Through 2030

Table 25 : Global Market for Oncology Biosimilars, by Region, Through 2030

Table 26 : North American Market for Oncology Biosimilars, by Indication, Through 2030

Table 27 : North American Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 28 : North American Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 29 : North American Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 30 : North American Market for Oncology Biosimilars, by Country, Through 2030

Table 31 : U.S. Market for Oncology Biosimilars, by Indication, Through 2030

Table 32 : U.S. Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 33 : U.S. Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 34 : U.S. Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 35 : Canadian Market for Oncology Biosimilars, by Indication, Through 2030

Table 36 : Canadian Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 37 : Canadian Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 38 : Canadian Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 39 : Mexican Market for Oncology Biosimilars, by Indication, Through 2030

Table 40 : Mexican Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 41 : Mexican Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 42 : Mexican Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 43 : European Market for Oncology Biosimilars, by Indication, Through 2030

Table 44 : European Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 45 : European Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 46 : European Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 47 : European Market for Oncology Biosimilars, by Country, Through 2030

Table 48 : German Market for Oncology Biosimilars, by Indication, Through 2030

Table 49 : German Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 50 : German Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 51 : German Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 52 : U.K. Market for Oncology Biosimilars, by Indication, Through 2030
Table 53 : U.K. Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 54 : U.K. Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 55 : U.K. Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 56 : French Market for Oncology Biosimilars, by Indication, Through 2030
Table 57 : French Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 58 : French Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 59 : French Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 60 : Italian Market for Oncology Biosimilars, by Indication, Through 2030
Table 61 : Italian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 62 : Italian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 63 : Italian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 64 : Spanish Market for Oncology Biosimilars, by Indication, Through 2030
Table 65 : Spanish Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 66 : Spanish Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 67 : Spanish Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 68 : Rest of Europe Market for Oncology Biosimilars, by Indication, Through 2030
Table 69 : Rest of Europe Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 70 : Rest of Europe Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 71 : Rest of Europe Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 72 : Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030
Table 73 : Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 74 : Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 75 : Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 76 : Asia-Pacific Market for Oncology Biosimilars, by Country, Through 2030
Table 77 : Chinese Market for Oncology Biosimilars, by Indication, Through 2030
Table 78 : Chinese Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 79 : Chinese Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 80 : Chinese Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 81 : Japanese Market for Oncology Biosimilars, by Indication, Through 2030

Table 82 : Japanese Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 83 : Japanese Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 84 : Japanese Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 85 : Indian Market for Oncology Biosimilars, by Indication, Through 2030

Table 86 : Indian Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 87 : Indian Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 88 : Indian Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 89 : South Korean Market for Oncology Biosimilars, by Indication, Through 2030

Table 90 : South Korean Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 91 : South Korean Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 92 : South Korean Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 93 : Australian Market for Oncology Biosimilars, by Indication, Through 2030

Table 94 : Australian Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 95 : Australian Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 96 : Australian Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 97 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030

Table 98 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 99 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 100 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 101 : MEA Market for Oncology Biosimilars, by Indication, Through 2030

Table 102 : MEA Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 103 : MEA Market for Oncology Biosimilars, by Route of Administration, Through 2030

2030

Table 104 : MEA Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 105 : MEA Market for Oncology Biosimilars, by Sub-region, Through 2030

Table 106 : Middle East Market for Oncology Biosimilars, by Indication, Through 2030

Table 107 : Middle East Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 108 : Middle East Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 109 : Middle East Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 110 : African Market for Oncology Biosimilars, by Indication, Through 2030

Table 111 : African Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 112 : African Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 113 : African Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 114 : South American Market for Oncology Biosimilars, by Indication, Through 2030

Table 115 : South American Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 116 : South American Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 117 : South American Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 118 : South American Market for Oncology Biosimilars, by Country, Through 2030

Table 119 : Brazilian Market for Oncology Biosimilars, by Indication, Through 2030

Table 120 : Brazilian Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 121 : Brazilian Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 122 : Brazilian Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 123 : Argentine Market for Oncology Biosimilars, by Indication, Through 2030

Table 124 : Argentine Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 125 : Argentine Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 126 : Argentine Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 127 : Rest of South America Market for Oncology Biosimilars, by Indication, Through 2030

Table 128 : Rest of South America Market for Oncology Biosimilars, by Drug Class, Through 2030

Table 129 : Rest of South America Market for Oncology Biosimilars, by Route of Administration, Through 2030

Table 130 : Rest of South America Market for Oncology Biosimilars, by Distribution Channel, Through 2030

Table 131 : Strategic Initiatives for Oncology Biosimilars Market, 2024–2025

Table 132 : Abbreviations Used in the Global Oncology Biosimilars Market

Table 133 : Accord Healthcare: Company Snapshot

Table 134 : Accord Healthcare: Product Portfolio

Table 135 : Alvotech: Company Snapshot

Table 136 : Alvotech: Financial Performance, FY 2023 and 2024

Table 137 : Alvotech: Product Portfolio

Table 138 : Alvotech: News/Key Developments, 2024–2025

Table 139 : Amgen Inc.: Company Snapshot

Table 140 : Amgen Inc.: Financial Performance, FY 2023 and 2024

Table 141 : Amgen Inc.: Product Portfolio

Table 142 : Amneal Pharmaceuticals LLC.: Company Snapshot

Table 143 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024

Table 144 : Amneal Pharmaceuticals LLC.: Product Portfolio

Table 145 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023–2025

Table 146 : Apotex Inc.: Company Snapshot

Table 147 : Apotex Inc.: Product Portfolio

Table 148 : Biocad: Company Snapshot

Table 149 : Biocad: Product Portfolio

Table 150 : Biocon Biologics Ltd.: Company Snapshot

Table 151 : Biocon Biologics Ltd.: Financial Performance, FY 2023 and 2024

Table 152 : Biocon Biologics Ltd.: Product Portfolio

Table 153 : Biocon Biologics Ltd.: News/Key Developments, 2023-2025

Table 154 : Celltrion Inc.: Company Snapshot

Table 155 : Celltrion Inc.: Financial Performance, FY 2023 and 2024

Table 156 : Celltrion Inc.: Product Portfolio

Table 157 : Celltrion Inc.: News/Key Developments, 2025

Table 158 : Fresenius Kabi AG: Company Snapshot

Table 159 : Fresenius Kabi AG: Product Portfolio

Table 160 : Fresenius Kabi AG: News/Key Developments, 2023-2025

Table 161 : Pfizer Inc.: Company Snapshot

Table 162 : Pfizer Inc.: Financial Performance, FY 2023 and 2024

Table 163 : Pfizer Inc.: Product Portfolio

Table 164 : Pfizer Inc.: News/Key Developments, 2023–2025

Table 165 : Samsung Bioepis: Company Snapshot

Table 166 : Samsung Bioepis: Product Portfolio

Table 167 : Samsung Bioepis: News/Key Developments, 2024

Table 168 : Sandoz Group AG: Company Snapshot

Table 169 : Sandoz Group AG: Financial Performance, FY 2023 and 2024

Table 170 : Sandoz Group AG: Product Portfolio

Table 171 : Sandoz Group AG: News/Key Developments, 2024–2025

Table 172 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 173 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024

Table 174 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 175 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023–2025

Table 176 : Viatris Inc.: Company Snapshot

Table 177 : Viatris Inc.: Financial Performance, FY 2023 and 2024

Table 178 : Viatris Inc.: Product Portfolio

Table 179 : List of a Few Emerging Startups

List Of Figures

LIST OF FIGURES

Summary Figure : Global Market Shares for Oncology Biosimilars, by Region, 2024

Figure 1 : Porter's Five Forces Analysis – Oncology Biosimilars Market

Figure 2 : Global Market Dynamics of Oncology Biosimilars

Figure 3 : Global Market Shares for Oncology Biosimilars, by Indication, 2024

Figure 4 : Global Market Shares for Breast Cancer, by Region, 2024

Figure 5 : Global Market Shares for Lung Cancer, by Region, 2024

Figure 6 : Global Market Shares for Blood Cancer, by Region, 2024

Figure 7 : Global Market Shares for Other Types of Cancer, by Region, 2024

Figure 8 : Global Market Shares for Oncology Biosimilars, by Drug Class, 2024

Figure 9 : Global Market Shares for Granulocyte Colony-Stimulating Factor, by Region, 2024

Figure 10 : Global Market Shares for Monoclonal Antibodies, by Region, 2024

Figure 11 : Global Market Shares for Hematopoietic Agents, by Region, 2024

Figure 12 : Global Market Shares for Other Drug Classes, by Region, 2024

Figure 13 : Global Market Shares for Oncology Biosimilars, by Route of Administration, 2024

Figure 14 : Global Market Shares for Intravenous Route of Administration, by Region, 2024

Figure 15 : Global Market Shares for Subcutaneous Route of Administration, by Region, 2024

Figure 16 : Global Market Shares for Other Routes of Administration, by Region, 2024

Figure 17 : Global Market Shares for Oncology Biosimilars, by Distribution Channel, 2024

Figure 18 : Global Market Shares for Hospital Pharmacies for Oncology Biosimilars, by Region, 2024

Figure 19 : Global Market Shares for Retail Pharmacies for Oncology Biosimilars, by Region, 2024

Figure 20 : Global Market Shares for Online Pharmacies for Oncology Biosimilars, by Region, 2024

Figure 21 : Global Market Shares for Other Distribution Channels for Oncology Biosimilars, by Region, 2024

Figure 22 : Global Market Shares for Oncology Biosimilars, by Region, 2024

Figure 23 : North American Market Shares for Oncology Biosimilars, by Country, 2024

Figure 24 : European Market Shares for Oncology Biosimilars, by Country, 2024

Figure 25 : Asia-Pacific Market Shares for Oncology Biosimilars, by Country, 2024

Figure 26 : MEA Market Shares for Oncology Biosimilars, by Sub-region, 2024

Figure 27 : South American Market Shares for Oncology Biosimilars, by Country, 2024

Figure 28 : Global Market Share Analysis for Oncology Biosimilars, by Major Companies, 2024

Figure 29 : Alvotect: Revenue Share, by Country/Region, FY 2024

Figure 30 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024

Figure 31 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024

Figure 32 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024

Figure 33 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2024

Figure 34 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2024

Figure 35 : Celltrion Inc.: Revenue Share, by Business Unit, FY 2024

Figure 36 : Celltrion Inc.: Revenue Share, by Country/Region, FY 2024

Figure 37 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024

Figure 38 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024

Figure 39 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024

Figure 40 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024

Figure 41 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2024

Figure 42 : Viatris Inc.: Revenue Share, by Business Unit, FY 2024

Figure 43 : Viatris Inc.: Revenue Share, by Country/Region, FY 2024

I would like to order

Product name: Global Oncology Biosimilars Market

Product link: <https://marketpublishers.com/r/G9EFA4B13E29EN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9EFA4B13E29EN.html>